Ascent Wealth Partners’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
Ascent Wealth Partners's RXRX Position: Q3 2026 in Review
Ascent Wealth Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 35,484 shares — an estimated $130K sold.
Ascent Wealth Partners first reported a position in RXRX in Q2 2025 and held it in 5 quarters. The position peaked at $130K in Q2 2026. 277 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.
- Ascent Wealth Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Ascent Wealth Partners sold 35,484 Recursion Pharmaceuticals shares in Q3 2026, an estimated $130K.
- Ascent Wealth Partners first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 5 quarters.
- Ascent Wealth Partners's Recursion Pharmaceuticals position peaked at $130K in Q2 2026.
- 277 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.
Based on Ascent Wealth Partners's 13F filing for Q3 2026, filed 23 Oct 2026.